Top Update: Corona Remedies IPO Allotment Set for Finalisation After Massive 137x Subscription

Investors are closely tracking the allotment outcome of the Corona Remedies IPO after the issue saw an extraordinary 137.04x subscription on its final bidding day. Strong demand from QIBs at 278.52x and NIIs at 208.88x pushed the issue into blockbuster territory, while the retail portion was oversubscribed nearly 29x. The ₹655.37 crore OFS only issue, priced at ₹1,008–1,062 per share, attracted bids for over 62 crore shares against just 45.72 lakh on offer.